Analysis of the difference in SLCO1B1 and APOE gene polymorphisms between Mongolian and Han populations

Area of Science:

• Pharmacogenomics
• Cardiovascular Genetics
• Population Genetics

Background:

• Cardiovascular diseases (CVD) represent a significant health burden globally.
• Genetic polymorphisms, such as those in SLCO1B1 and APOE, are known to influence drug metabolism and disease susceptibility.
• Understanding population-specific genetic variations is crucial for personalized medicine.

Purpose of the Study:

• To investigate the prevalence and clinical significance of SLCO1B1 and APOE gene polymorphisms.
• To compare these polymorphisms between Mongolian and Han populations in Ordos, Inner Mongolia.
• To explore the potential impact of these genetic differences on CVD incidence and statin efficacy.

Main Methods:

• A case-control study involving 200 Mongolian and 200 Han patients with cardiovascular disease.
• Genotyping of SLCO1B1 and APOE polymorphisms using real-time fluorescence quantitative PCR (qPCR).
• Statistical analysis to compare demographic, clinical, and genetic data between the two ethnic groups.

Main Results:

• Both SLCO1B1 and APOE polymorphisms adhered to the Hardy-Weinberg equilibrium in both populations.
• Significant differences were observed in demographic factors (gender, age, BMI) and clinical characteristics (hypertension, dyslipidemia, LDL-C levels) between the groups.
• APOE genotypes, associated with statin efficacy and atherosclerosis risk, showed significant inter-population differences.

Conclusions:

• Distinct patterns of SLCO1B1 and APOE polymorphisms exist between the Mongolian and Han populations in Ordos.
• These genetic disparities may contribute to observed differences in cardiovascular disease prevalence.
• The findings suggest potential variations in statin-induced lipid-lowering effects between these ethnic groups.